Residual 18F-FDG-PET Uptake 12 Weeks After Stereotactic Ablative Radiotherapy for Stage I Non-Small-Cell Lung Cancer Predicts Local Control

To investigate the prognostic value of [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) uptake at 12 weeks after stereotactic ablative radiotherapy (SABR) for stage I non-small-cell lung cancer (NSCLC). From November 2006 to February 2010, 132 medically inoperable patients with proven...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of radiation oncology, biology, physics Vol. 83; no. 4; pp. e551 - e555
Main Authors Bollineni, Vikram Rao, Widder, Joachim, Pruim, Jan, Langendijk, Johannes A., Wiegman, Erwin M.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 15.07.2012
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:To investigate the prognostic value of [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) uptake at 12 weeks after stereotactic ablative radiotherapy (SABR) for stage I non-small-cell lung cancer (NSCLC). From November 2006 to February 2010, 132 medically inoperable patients with proven Stage I NSCLC or FDG-PET-positive primary lung tumors were analyzed retrospectively. SABR consisted of 60 Gy delivered in 3 to 8 fractions. Maximum standardized uptake value (SUVmax) of the treated lesion was assessed 12 weeks after SABR, using FDG-PET. Patients were subsequently followed at regular intervals using computed tomography (CT) scans. Association between post-SABR SUVmax and local control (LC), mediastinal failure, distant failure, overall survival (OS), and disease-specific survival (DSS) was examined. Median follow-up time was 17 months (range, 3–40 months). Median lesion size was 25 mm (range, 9–70 mm). There were 6 local failures: 15 mediastinal failures, 15 distant failures, 13 disease-related deaths, and 16 deaths from intercurrent diseases. Glucose corrected post-SABR median SUVmax was 3.0 (range, 0.55–14.50). Using SUVmax 5.0 as a cutoff, the 2-year LC was 80% versus 97.7% for high versus low SUVmax, yielding an adjusted subhazard ratio (SHR) for high post-SABR SUVmax of 7.3 (95% confidence interval [CI], 1.4–38.5; p = 0.019). Two-year DSS rates were 74% versus 91%, respectively, for high and low SUVmax values (SHR, 2.2; 95% CI, 0.8–6.3; p = 0.113). Two-year OS was 62% versus 81% (hazard ratio [HR], 1.6; 95% CI, 0.7–3.7; p = 0.268). Residual FDG uptake (SUVmax ≥5.0) 12 weeks after SABR signifies increased risk of local failure. A single FDG-PET scan at 12 weeks could be used to tailor further follow-up according to the risk of failure, especially in patients potentially eligible for salvage surgery.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0360-3016
1879-355X
DOI:10.1016/j.ijrobp.2012.01.012